The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Contemporary challenges in polycythemia vera management
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, comments on the contemporary challenges in polycythemia vera (PV) management from the perspective of patients and physicians. Although current agents effectively reduce thrombotic risk, they fail to improve some of the symptoms that negatively impact patients’ quality of life. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm; Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen; Advisory Board: Dark Blue Therapeutics.
